Suchergebnisse - "Siegel, Eric R"

PubPharm (52)

1

Prognostic value of ferritin in ASCT MM patients : integration with GEP models and ISS series systems

enthalten in: Blood cancer journal | 2024

von Guo, W. | Zhan, Y. | Mery, D. | +16

2

High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma

enthalten in: Cell reports. Medicine | 2023

von Cheng, Y. | Sun, F. | Alapat, D. | +26

CommentIn: Cell Rep Med. 2023 Oct 17;4(10):101237. - PMID 37852178

3

A gene signature can predict risk of MGUS progressing to multiple myeloma

enthalten in: Journal of hematology & oncology | 2023

von Sun, F. | Cheng, Y. | Ying, J. | +18

4

The effect of maternal pregestational diabetes on fetal autonomic nervous system

enthalten in: Physiological reports | 2023

von Mercado, L. | Escalona-Vargas, D. | Blossom, S. | +5

5

Clinical Impact of ASCO Choosing Wisely Guidelines on Staging Imaging for Early-Stage Breast Cancers : A Time Series Analysis Using SEER-Medicare Data

enthalten in: JCO oncology practice | 2023

von Baltz, A. | Siegel, E. | Kamal, A. | +5

6

Diffuse Reflectance Spectroscopy of Changes in Tumor Microenvironment in Response to Different Doses of Radiation

enthalten in: Radiation research | 2022

von Jules, A. | Means, D. | Troncoso, J. | +4

7

Social Needs of Patients Undergoing Total Joint Arthroplasty

enthalten in: The Journal of arthroplasty | 2022

von Norris, A. | Mears, S. | Siegel, E. | +2

8

Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer

enthalten in: British journal of cancer | 2022

von Roque, D. | Siegel, E. | Buza, N. | +18

ErratumIn: Br J Cancer. 2024 Mar 4;:. - PMID 38438590

9

A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability

enthalten in: Cancer | 2022

von Bellone, S. | Roque, D. | Siegel, E. | +30

CommentIn: Cancer. 2022 Mar 15;128(6):1157-1161. - PMID 34875102

10

Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu

enthalten in: Gynecologic oncology | 2021

von Tymon-Rosario, J. | Siegel, E. | Bellone, S. | +14

1
2
3
4
5
6
Nächster »
[6]